Human Immunodeficiency Virus (HIV)-1 Integration Sites in Viral Latency

Current HIV/AIDS Reports

Volumn 12, Issue 1, 2015, Pages 88-96

  Rezaei, Simin D ^a   Cameron, Paul U ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Cancer associated genes; CD4 T cells; HIV; Integration sites; Jurkat cell line; Latency; T cell clonal expansion; T cell subsets; Transcriptional interference; Transcriptional units

Indexed keywords

VIRUS ANTIGEN;

CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL GROWTH; CELL SURVIVAL; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LONGITUDINAL STUDY; NONHUMAN; PROMOTER REGION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS EXPRESSION; VIRUS GENE; DISEASE CARRIER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS DNA CELL DNA INTERACTION; VIRUS LATENCY;

DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; VIRUS INTEGRATION; VIRUS LATENCY;

EID: 84925460986     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0241-9     Document Type: Review

References (78)

1. Siliciano, R.F. and W.C. Greene, HIV latency. Cold Spring Harbor Perspectives in Medicine, 2011. 1(1).
2. Finzi D et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300.
3. Chun TW et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94(24):13193–7.
4. Ho DD et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123–6.
5. Chun TW et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1(12):1284–90.
6. Stellbrink HJ et al. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells. Aids. 1997;11(9):1103–10.
7. Chun TW et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000;6(7):757–61.
8. Buzon MJ. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med. 2014;20(2):139–42. This in vivo study demonstrates the ability of HIV-1 to generate stable latent reservoir in CD4 TSCM population derived from patients on suppressive antiretroviral therapy. It suggests HIV-1 can selectively seed into a T cell subset that has increased proliferative potential and low levels of virus expression.
9. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557–93.
10. Lugli E et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594–9.
11. Koenig S et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089–93.
12. Koppensteiner H, Brack-Werner R, Schindler M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology. 2012;9:82.
13. Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6(4):1837–60.
14. Chomont N et al. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS. 2011;6(1):30–6.
15. Bosque A et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog. 2011;7(10):e1002288.
16. Chomont N et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893–900.
17. Chun TW et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A. 2003;100(4):1908–13.
18. Hermankova M et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol. 2003;77(13):7383–92.
19. Shan L. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011;85(11):5384–93.
20. Mitchell RS et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2(8):E234.
21. Schroder AR et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521–9.
22. Elleder D et al. Preferential integration of human immunodeficiency virus type 1 into genes, cytogenetic R bands and GC-rich DNA regions: insight from the human genome sequence. FEBS Lett. 2002;517(1–3):285–6.
23. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo j. 2003;22(8):1868–77.
24. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J. 2001;20(7):1726–38.
25. Wang GP et al. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007;17(8):1186–94.
26. Pearson R et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol. 2008;82(24):12291–303.
27. Gallastegui E et al. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol. 2011;85(7):3187–202.
28. Derse D et al. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol. 2007;81(12):6731–41.
29. Hematti P et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2(12):e423.
30. Wu X et al. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300(5626):1749–51.
31. Cherepanov P et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem. 2003;278(1):372–81.
32. Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 2006;22(7):388–95.
33. Llano M et al. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol. 2004;78(17):9524–37.
34. Ferris AL et al. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc Natl Acad Sci U S A. 2010;107(7):3135–40.
35. Gijsbers R et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol Ther. 2010;18(3):552–60.
36. Schrijvers R. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 2012;8(3):e1002558. This study identifies the host cellular factors crucial for the preferred site of HIV-1 proviral integration into host genome. It clearly demonstrates the role of LEDGF/p75 in specifically directing HIV-1 integration into active transcriptional units outside promoter regions.
37. Gijsbers R. Role of the PWWP domain of lens epithelium-derived growth factor (LEDGF)/p75 cofactor in lentiviral integration targeting. J Biol Chem. 2011;286(48):41812–25. This in vitro study demonstrates the effect of host cellular protein to selectively lead to integration of HIV-1 provirus into specific region in host genome.
38. Mahmoudi T. The BAF complex and HIV latency. Transcription. 2012;3(4):171–6.
39. Rafati H et al. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 2011;9(11):e1001206.
40. Arimondo PB et al. The chromosomal protein HMG-D binds to the TAR and RBE RNA of HIV-1. FEBS Lett. 2000;485(1):47–52.
41. Hindmarsh P et al. HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J Virol. 1999;73(4):2994–3003.
42. Lewinski MK et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2006;2(6):e60.
43. Christ F et al. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother. 2012;56(8):4365–74.
44. Dahabieh MS et al. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFkappaB. Retrovirology. 2014;11:17.
45. Dieudonne M et al. Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery. Embo j. 2009;28(15):2231–43.
46. Carteau S, Hoffmann C, Bushman F. Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol. 1998;72(5):4005–14.
47. Han Y et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe. 2008;4(2):134–46.
48. Duverger A et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol. 2009;83(7):3078–93.
49. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe. 2008;4(2):123–33.
50. Shearwin KE, Callen BP, Egan JB. Transcriptional interference—a crash course. Trends Genet. 2005;21(6):339–45.
51. Cullen BR, Lomedico PT, Ju G. Transcriptional interference in avian retroviruses—implications for the promoter insertion model of leukaemogenesis. Nature. 1984;307(5948):241–5.
52. Han Y et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol. 2004;78(12):6122–33.
53. Vatakis DN et al. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol. 2009;83(12):6222–33.
54. Barr SD et al. HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. Mol Ther. 2006;14(2):218–25.
55. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665–708.
56. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
57. Pierson TC et al. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol. 2002;76(8):4138–44.
58. Bukrinsky MI et al. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 1991;254(5030):423–7.
59. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol. 1995;69(5):2977–88.
60. Saleh S et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007;110(13):4161–4.
61. Cameron PU et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A. 2010;107(39):16934–9.
62. Evans VA et al. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog. 2013;9(12):e1003799.
63. Shen A et al. Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. J Virol. 2013;87(17):9768–79.
64. Pace MJ. Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog. 2012;8(7):e1002818. This in vitro study of a primary T cell latency model demonstrates that latently infected cells can express intracellular viral proteins without spreading infection and that epigenetic modifiers are common between expressing and non-expressing cells but do not associate with cell activation.
65. Brady T et al. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS. 2009;23(12):1461–71.
66. Sherrill-Mix S. HIV latency and integration site placement in five cell-based models. Retrovirology. 2013;10:90. This study extends the observations of Pace et al. in a critical analysis of integration sites in silent/inducible and expressed virus across 5 in vitro models of primary T cell latency and showed no significant differences in genomic features associated with integration sites across the 5 models. However, within models provirus in the same chromosomal region tended to share the same expression status.
67. Ho YC. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;55(3):540––51. This in vivo study demonstrates the presence of a large pool of unactivatable replication competent provirus resident in the latent reservoir. This pool is much larger than latent pool measured by viral outgrowth assays.
68. Maldarelli F. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345(6193):179–83. This in vivo study demonstrates the detection of unique integration site in clonally expanded cells derived from patients on therapy suggesting clonal expansion of the infected cells and persistence of the viral reservoir through clonal expansion of cells. Multiple non-identical insertions suggest changes in specific genes are driving this process.
69. Wagner TA. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345(6196):570–3. This in vivo study demonstrates the integration of HIV-1 provirus in cancer associated genes and highlighted the effect of the integration in expression of cancer related genes that may promote survival of infected cells over time.
70. Wei X et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373(6510):117–22.
71. Imamichi H. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. Aids. 2014;28(8):1091–9. This in vivo study shows clonal expansion of a very rare CD4 T cell subset containing HIV-1 integrated provirus over a period of 15 years in a well-suppressed patient on therapy, suggesting HIV-1 proviral integration site affects cell growth and cell survival of the infected cell.
72. Ikeda T et al. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis. 2007;195(5):716–25.
73. Gattinoni L et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–7.
74. Macallan DC et al. Rapid turnover of effector—memory CD4+ T cells in healthy humans. The Journal of Experimental Medicine. 2004;200(2):255–60.
75. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science. 2000;290(5489):92–7.
76. Lewinski MK et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol. 2005;79(11):6610–9.
77. De Palma M et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood. 2005;105(6):2307–15.
78. Liu H et al. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes. J Virol. 2006;80(15):7765–8.